GBS(US:INBS) Globenewswire·2025-10-30 12:30Core Insights - Intelligent Bio Solutions Inc. reported a 50% increase in new customer accounts during the fiscal first quarter, totaling over 480 active accounts, indicating strong customer expansion and revenue momentum [1][3][4] Company Performance - The company added 33 new customer accounts in the fiscal first quarter ended September 30, 2025, compared to the same period last year [1] - Approximately 91% of new accounts were first-time adopters of the drug screening solution, while 9% were expansions within existing customer organizations [3] - The company aims to convert current momentum into sustained revenue growth and long-term value [3] Market Trends - The global drug screening market is projected to reach USD 17.1 billion by 2029, growing at a CAGR of 15%, driven by increasing regulatory focus on workplace safety and demand for non-invasive testing solutions [4] - Adoption of the Intelligent Fingerprinting Drug Screening System is broadening across various industries, reflecting its scalability and alignment with modern compliance standards [5] Sector Growth - Strongest growth in customer acquisition was noted in sectors such as maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration [2] - Government administration is a newly entered sector, highlighting the expanding applicability of the company's solutions [2]